NEJM Original Article
The New England Journal of Medicine, February 9, 2024
Data from a multicenter, randomized, dose-finding trial of 255 patients with moderate-to-severe plaque psoriasis. Patients were randomly assigned to receive treatment at varying dosages with a novel orally administered interleukin-23-receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production or a placebo for 16 weeks.
What’s Interesting about this article?
- The use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis.
- However, monoclonal antibodies are large proteins, which must be administered by injection.
- The treatment of patients with this new orally administered drug showed greater efficacy than placebo.
- Development of an effective psoriasis drug that can be taken by mouth is a great benefit for patients.
- In an accompanying editorial by Joel M. Gelfand, M.D., the doctor points out that advances in bioengineering have made it possible to administer large complex proteins by mouth, with semiglutide being a notable example.
- This study focused on changes in the skin. It is not known what effect this drug will have on other organs or disorders affected by psoriasis, such as arthritis.
Disclaimer: Article of the Week selections by JournalDoc physicians are independent, unbiased and have no commercial conflict of interest. JournalDoc does not support or endorse the findings or opinions expressed in the article. Findings in the article may need to be supported by further research and/or the consensus of experts.